Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Chronic Myeloid Leukemia

Rowley, J. (1973) "A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining", Nature 43, 290–293.

Daley, G.Q., Van Erten, R.A. and Baltimore, D. (1990) "Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gen of the Philadelphia chromosome", Science 247, 824–830.

Goldman, J., Szycllo, R., Horowitz, M.M., Gale, R.P., Ash, R.C., Atkinson, K., Dicke, K.A., Gluckman, E., Herzig, R.H. and Marmont, A. (1993) "Choice of pretransplant treatment and timing of transplant for chronic myelogenous leukemia in chronic phase", Blood 82, 2235–2238.

Druker, B., Talpaz, M., Resta, D., Bin Peng, RN., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", N. Engl. J. Med. 344, 1031–1037.

Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoeliner, U., Talpaz, M. and Drucker, B. (2002) "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", N. Engl. J. Med. 346, 645–652.

Kitiyakara, C. and Atichartakarn, V. (2002) "Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, 5TI571", NDT 17, 685–687.

Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, GM., Fanning, S., Zimmermann, J. and Lydon, N.B. (1996) "Effects of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nat. Med. 2, 561–566.

Gilbert, R.E., Kelly, D.J., McKay, T., Chadban, S., Hill, P.A., Cooper, ME., Atkins, R.C. and Nikolic-Paterson, D.J. (2001) "PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis", Kidney Int. 59, 1324–1332.